Prospective multicenter observational study of atezolizumab combination therapy in patients with unresectable, advanced and recurrent non-small cell lung cancer or extensive disease small cell lung cancer
Latest Information Update: 15 Jul 2024
Price :
$35 *
At a glance
- Drugs Atezolizumab (Primary) ; Antineoplastics
- Indications Non-small cell lung cancer; Small cell lung cancer
- Focus Therapeutic Use
- Acronyms J-TAIL-2
- Sponsors Chugai Pharmaceutical
- 04 Jun 2024 Results (data cut off (Feb 3, 2023), N=814) assessing the efficacy and safety of 3 atezo combination therapies for NSCLC in the clinical setting in Japan were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2024 Results (n=403, data cutoff (Feb 3, 2023)) evaluating the efficacy and safety of atezo + CE in Japanese pts in the clinical setting were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 01 Apr 2024 Status changed from active, no longer recruiting to completed.